Evidence map›Paper›PMID 36010285›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Identification of EGFR as a Biomarker in Saliva and Buccal Cells from Oral Submucous Fibrosis Patients-A Baseline Study.

Abirami Moorthy, Divyambika Catakapatri Venugopal, Vidyarani Shyamsundar, Yasasve Madhavan, Soundharya Ravindran, Mehanathan Kuppuloganathan, Arvind Krishnamurthy, Sathasivasubramanian Sankarapandian, Vani Ganapathy, Vijayalakshmi Ramshankar

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Abirami MoorthyDepartment of Oral Medicine and Radiology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India.
Divyambika Catakapatri VenugopalDepartment of Oral Medicine and Radiology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India.ORCID 0000-0002-1344-8678
Vidyarani ShyamsundarCentre for Oral Cancer Prevention and Research, Sree Balaji Dental College and Hospital, Pallikaranai, Chennai 600100, India.
Yasasve MadhavanDepartment of Oral Medicine and Radiology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India.ORCID 0000-0001-7029-3679
Soundharya RavindranDepartment of Preventive Oncology (Research), Cancer Institute (WIA), Adyar, Chennai 600020, India.
Mehanathan KuppuloganathanDepartment of Preventive Oncology (Research), Cancer Institute (WIA), Adyar, Chennai 600020, India.
Arvind KrishnamurthyDepartment of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai 600020, India.
Sathasivasubramanian SankarapandianDepartment of Oral Medicine and Radiology, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India.
Vani GanapathyDepartment of Biochemistry, University of Madras, Chennai 600025, India.
Vijayalakshmi RamshankarDepartment of Preventive Oncology (Research), Cancer Institute (WIA), Adyar, Chennai 600020, India.
Cancer Institute (WIA) · INSri Ramachandra Institute of Higher Education and Research · INSree Balaji Dental College and Hospital · INUniversity of Madras · IN

Funding

Indian Council of Medical Research 2019-06006
6 · The paper itself

Abstract

Oral Submucous Fibrosis (OSMF) is a chronic debilitating disease more frequently encountered in the South-East Asian population. This disease represents a public health priority as it is grouped within oral potentially malignant disorders, with malignant transformation rates of around 7-19%. Hence, early identification of high-risk OSMF patients is of the utmost importance to prevent malignant transformation. Among various biomarkers, EGFR overexpression has an unfavorable clinical outcome, poor prognosis, and low survival rates in Oral Squamous Cell Carcinoma (OSCC). The current study aimed to evaluate the expression of EGFR in saliva and exfoliated buccal cells of OSMF. Immunoexpression of EGFR was observed in healthy controls (n = 11), OSCC (n = 106), and OPMD with dysplasia (n = 56), which showed significant expression with increasing grades of dysplasia and OSCC. EGFR expression was evaluated in saliva and exfoliated buccal cells of healthy controls (n = 15), OSMF (n = 24), and OSCC (n = 10) patients using ELISA, which revealed significant expression in OSMF and OSCC. Validation studies were also performed using real-time PCR (RT-PCR) to compare gene expression in healthy controls (n = 9), OSMF (n = 9), and OSCC (n = 25), which showed significant 18-fold upregulation in OSCC and three-fold upregulation in OSMF when compared to healthy controls. Hence, saliva and exfoliated buccal cells could be considered as potential non-invasive diagnostic samples for the evaluation of high-risk patients of OSMF using EGFR as a biomarker.

Indexed as

biomarkerEGFRELISAimmunohistochemistryOSMF

Identifiers

PMID36010285
PMCPMC9406318
OpenAlexW4291016545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.